|
Re: like the song "AT LAST": her2+ breast cancer subtypes are being IDd, best treatme
I don't see this on the Clinical Cancer Research site. It looks like they are a day behind (most recent "online first" postings are 1/16). I'm especially curious about what kind of distribution of the subtypes they observed, and details of ER r/t subtype. For example, are the majority of HER2+ cancers HER2-enriched, or is it more even across all the observed subtypes?
If anyone has found access to the full text, would you let us know?
Thanks,
Debbie Laxague
__________________
3/01 ~ Age 49. Occult primary announced by large (6cm) axillary node, found by my husband.
4/01 ~ Bilateral mastectomies (LMRM, R elective simple) - 1.2cm IDC was found at pathology. 5 of 11 axillary nodes positive, largest = 6cm. Stage IIIA
ERPR 5%/1% (re-done later at Baylor, both negative at zero).
HER2neu positive by IHC and FISH (8.89).
Lymphovascular invasion, grade 3, 8/9 modified SBR.
TX: Control of arm of NSABP's B-31 adjuvant Herceptin trial (no Herceptin, inducing a severe case of Herceptin-envy): A/C x 4 and Taxol x 4 q3weeks, then rads. Raging infection of entire chest after small revision of mastectomy scar after completing tx (significance unknown). Arimidex for two years, stopped after second pathology opinion.
2017: Mild and manageable lymphedema and some cognitive issues.
|